tilsotolimod
idera
['intrim', 'imo-2125', 'melanoma', 'medsir']
interim analysis results of the ph 2 intrim study show intradermal imo-2125 vs placebo as adjuvant treatment in pts with stage ii pt3-4/cn0 melanoma, reduces tumor-positive sentinel lymph node rates (13% vs. 45%) with manageable toxicity. talk by #jessicanotohardjo #esmo22 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM